Business
Akili Releases EndeavorOTC - Adult ADHD Treatment
Akili Releases EndeavorOTC - Adult ADHD Treatment.
About this update from Puretech Health Plc
[{"type":"text","content":"\n\n7 June 2023\nPureTech Health plc\n \nPureTech Founded Entity Akili Releases EndeavorOTCTM Video Game Treatment to Improve Attention in Adults with ADHD\n \nAmid growing mental health crisis, the product release enables immediate access to non-drug treatment option as Akili prepares FDA submission\n \nAvailable nationwide without a prescription, clinical data shows improvements in focus in 83% of adults with ADHD\n \nPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (\"PureTech\" or the \"Company\"), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) (\"Akili\"), a leading digital medicine company, today released EndeavorOTCTM, a new immersive mobile video game treatment that is clinically proven to improve attention and focus, specifically in adults with ADHD. EndeavorOTC is built on the same technology as Akili's EndeavorRxⓇ, the world's first and only FDA-authorized video game treatment now being prescribed for children 8-12 years old with ADHD. EndeavorOTC is now available without a prescription for adults 18 years and older nationwide.\n \nThis announcement comes on the heels of recently announced clinical trial data showing that EndeavorOTC (AKL-T01) significantly improved focus, attention, and overall quality of life in adults struggling with ADHD symptoms:\n● 83% of participants reported clinical improvements in their focus\n● On average, participants' ability to focus improved by 85%\n● Over one-third of participants no longer exhibited an attention deficit following treatment\n● 73% of participants reported quality of life improvements, including completing tasks on time, managing multiple tasks at once, and keeping track of important items like wallets or keys\n \nAmid a persistent mental health crisis, an increasing number of adults are seeking help for ADHD symptoms including inattention and lack of focus while facing an ongoing nationwide shortage of ADHD medication. As the gap between demand for care and availability of effective treatments widens, Akili released EndeavorOTC under FDA's enforcement policy established shortly after the onset of the COVID-19 pandemic to facilitate rapid access to certain low-risk, mental health-related digi...